CAS: 213764-25-1; Cyclopropylhydrazine Hydrochloride
该化合物是一种化学化合物,其特征是,氢丙基脊柱,配有环丙基组,以及盐盐状,该化合物一般是白色的,白外晶状固体,在水中溶解,这是许多氢氨衍生物的一个常见特征,主要用于各种化学合成,由于其核生殖特性,可用作有机化学的试剂.环丙基组的存在可影响该化合物的再活动性和稳定性,并可能影响其在制药或农用化学中的应用.与许多氢丙基衍生物一样,必须谨慎地处理该化合物,因为其潜在毒性和再活性,特别是在存在氧化剂的情况下.应参考安全数据表,以进行适当的处理和处置.
- 英文名称Cyclopropylhydrazine Hydrochloride
- 中文名称环丙基肼盐酸盐
- IUPAC名称cyclopropylhydrazine hydrochloride
- 其它别名环丙基肼单盐酸盐; Hydrazine, Cyclopropyl-, Monohydrochloride
- CAS编号213764-25-1
- MFCD编号:MFCD16658753
- EINECS号:810-789-0
- 分子式:C3H9ClN2分子量:108.57
- 产品CID: 1104410
- 产品分类有机原料→分子砌块→脂肪链类化合物
相似化合物
1374652-23-9 848153-29-7 1219020-59-3物理性质
MSDS等安全信息
合成工艺路线路线简述
📜1-环丙基肼-1,2-二羧酸二叔丁酯置于乙酰氯,盐酸体系中,用 甲醇 用作溶剂,化学反应生成环丙基肼盐酸盐
参考文献:铈光催化使未活化的羧酸脱羧酰化†
标题:铈光催化使未活化的羧酸脱羧酰化†
摘要:我们报告了铈与偶氮二羧酸二叔丁酯(dbad)的铈的光催化自由基脱羧肼化反应.该操作简单的方案提供了对合成有用的肼衍生物的快速访问,并克服了光氧化还原催化的羧酸脱羧中的当前范围限制.
Doi:10.1039/c9Cc00492K
专利信息
专利号:US-2025304580-A1
优先权日:2021-11-09
标 题:Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; PANDYA BHAUMIK; KAPLAN ALAN P; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2†).This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
专利号:US-2025042881-A1
优先权日:2021-10-26
标 题 :Ccr6 receptor modulators
发明人：ALLEMANN OLIVER; CAROFF EVA; HUBLER FRANCIS; MEYER EMMANUEL
权利人:IDORSIA PHARMACEUTICALS LTD
摘要:The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the prevention or treatment of e.g. inflammatory/autoimmune diseases/disorders and cancer.
专利号:US-9714226-B2
优先权日:2011-07-29
标题:Hydrazide containing nuclear transport modulators and uses thereof
发明人：SANDANAYAKA VINCENT P; SHACHAM SHARON; MCCAULEY DILARA; SHECHTER SHARON
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: n nor a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
